RBC Capital affirms Gilead (Nasdaq: GILD) at Outperform with a price target of $115 following FDA approval of Harvoni (ledipasvir ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE